Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK – Get Free Report) announced a dividend on Thursday, May 16th, investing.com reports. Shareholders of record on Tuesday, May 21st will be paid a dividend of 15.10 per share by the biopharmaceutical company on Friday, May 17th. This represents a yield of 99.87%. The ex-dividend date is Monday, May 20th. This […]
StockNews.com cut shares of Merrimack Pharmaceuticals (NASDAQ:MACK – Free Report) from a hold rating to a sell rating in a research report released on Monday morning. Merrimack Pharmaceuticals Trading Up 0.1 % Merrimack Pharmaceuticals stock opened at $15.13 on Monday. The firm has a market capitalization of $219.84 million, a P/E ratio of -189.13 and […]
Merrimack Pharmaceuticals (NASDAQ:MACK) Stock Rating Upgraded by StockNews.com theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK – Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $12.55 and traded as high as $13.47. Merrimack Pharmaceuticals shares last traded at $13.44, with a volume of 29,917 shares traded. Analysts Set New Price Targets Separately, StockNews.com […]
Merrimack Pharmaceuticals (NASDAQ:MACK – Get Free Report) and Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership. Earnings & Valuation This table compares Merrimack […]